- Current languageen
Pharmaceuticals - Community Register
Community register of veterinary medicinal products
|Invented name:||Equilis West Nile|
|Auth. number :||EU/2/13/151|
|Active substance :||Inactivated chimeric flavivirus strain YF-WN|
|ATC:||Anatomical main group: QI - Immunologicals|
Therapeutic subgroup: QI05 - Immunologicals for equidae
Pharmacological subgroup: QI05A - Horse
Chemical subgroup: QI05AA - Inactivated viral vaccines
Chemical substance: QI05AA10 - West nile virus
(See WHO ATCvet Index)
|Indication:||Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia. |
Onset of immunity: 2 weeks after primary vaccination course of two injections.
Duration of immunity: 12 months.
|Marketing Authorisation Holder:||Intervet International B.V.
Wim de Körverstraat 35, NL-5831 AN Boxmeer, Nederland
|EPAR and active package presentations|
Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".|
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.
|Close date procedure||Procedure type||EMEA number||Decision||summary publ||decision docs||annex|
|10/06/2013||Centralised - Authorisation||EMEA/V/C/2241||(2013)3515 of 06/06/2013|